Summary To evaluate the diagnostic application of serum a-fetoprotein (AFP) and circulating immune complexes (CICs), AFP, 3% polyethylene glycol (PEG)-CICs, 4% PEG-CICs, and Clq-CICs were determined in 101 patients with cirrhosis alone, 101 sex-matched and age-matched cirrhotic patients with hepatocellular carcinoma (HCC) and 54 healthy controls. Multivariate analysis indicated that AFP (odds ratio 1.014; 95% confidence interval 1.004-1.024) and 3% PEG-CICs (odds ratio 1.011; 95% confidence interval 1.005-1.017) are associated, in a dose-related fashion, with an increased risk for HCC. A receiver operative characteristic (ROC) curve was used to determine the optimal cut-off values of AFP (120 ng ml-') and 3% PEG-CICs (310 jg aggregated IgG equivalent ml-'). The area under ROC curve was 0.875 for AFP and 0.812 for 3% PEG-CIC. Both AFP and 3% PEG-CICs show a high specificity (100%) and positive likelihood ratio. The sensitivity was 65.3% for 3% PEG-CICs and 67.3% for AFP. Determination of both markers in parallel significantly increase the diagnostic accuracy (92.1%) and sensitivity (84%), with a high specificity (100%) and positive likelihood ratio (> 84). In conclusion, both 3% PEG-CICs and AFP are independent risk factors of HCC, and may be used as complementary tumour markers to discriminate HCC from cirrhosis. Determination of 3% PEG-CICs should be performed in cirrhotics negative for AFP to improve detection of HCC.
Hepatocellular carcinoma (HCC) appears to be associated with hepatitis B and C virus infection and is common in patients with cirrhosis caused by chronic viral hepatitis (Jeng and Tsai, 1991; Simonetti et al., 1991; Tsai et al., 1993 Tsai et al., , 1994a . HCC usually presents late, and patients are generally in poor clinical condition when diagnosed. An effective screening system to detect HCC at an early stage may result in more effective treatment. The lack of symptoms in the early stage of HCC makes screening of patients at risk for HCC impractical. a-Fetoprotein (AFP) is an oncofetal protein produced by HCC. Although the role of AFP in the diagnosis of advanced HCC is well recognised, at least onethird of small HCCs and 10% of advanced HCCs will be missed unless another diagnostic tool is used (Chen and Sung, 1977; Lee et al., 1991; Sherlock and Dooley, 1993; Tsai et al., 1994b) . In addition, AFP may be increased in nonmalignant liver disease (Chen and Sung, 1977; Sherlock and Dooley, 1993) . These shortcomings have motivated many investigators to search for other better tumour markers for HCC.
There is increasing evidence that experimental tumourbearing animals and patients with cancer have increased levels of circulating immune complexes (CICs) (Brown et al., 1983 (Brown et al., , 1984 Neri, 1983; Salinas et al., 1983; Coursaget et al., 1986; Tsai et al., 1990a Tsai et al., , 1991 Tabor, 1991) . The finding of a correlation between CIC levels and extent of tumour burden led to the expectation that determination of CIC levels might be useful in monitoring the clinical course of the disease (Neri, 1983; Salinas et al., 1983; Brown et al., 1984; . CICs have been shown in patients with HCC (Brown et al., 1983 (Brown et al., , 1984 Coursaget et al., 1986; Tsai et al., 1990a Tsai et al., , 1991 Tabor, 1991) and could be used as a marker to monitor therapy in HCC . However, the role of CICs as a diagnostic marker has never been clearly elucidated.
Liver cirrhosis (LC) is considered to be a premalignant condition of HCC. Between 2.2% and 55% of autopsied cirrhotics have HCC, and about 80% of HCC patients have associated cirrhosis (Tsai et al., 1990a (Tsai et al., , 1994a Jeng and Tsai, 1991; Simonetti et al., 1991; Sherlock and Dooley, 1993 Sensitivity, specificity, positive and negative predictive value, positive and negative likelihood ratio and diagnostic accuracy were calculated according to the following formula (Sox et al., 1989) :
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Negative predictive value = d/(c + d) Positive likelihood ratio = sensitivity/(l -specificity) Negative likelihood ratio = (1-sensitivity)/specificity where a = true-positive cases, b = false-positive cases, c = false-negative cases and d = true-negative cases. Receiver operating characteristic (ROC) curves were constructed by calculating the sensitivities and specificities of AFP or CIC assays at several cut-off points. The differences in diagnostic accuracy between the marker tests were measured by McNemar's test.
Results
CIC levels in patients with HCC, LC and controls As shown in Table I , the levels of Clq-CICs and 3% PEGCICs in patients with HCC were higher than in controls (P <0.0001). The 4% PEG-CIC level was lower in the former than that in the latter (P<0.01). Patients with HCC also had significantly higher levels of 3% PEG-CICs and 4% PEGCICs when compared with LC patients (P<0.001 and P<0.01 respectively). There were positive correlations between 3% PEG-CICs and prothrombin time (r = 0.32, P<0.01), globulin (r = 0.39, P<0.0001), total and direct bilirubin (r= 0.54, P<0.0001, and r=0.53, P<0.0001, respectively), y-glutamyltranspeptidase (r = 0.35, P<0.001) and alanine transaminase (r = 0.24, P<0.05). There were negative correlations between 3% PEG-CICs and albumin (r=-0.21, P<0.04). There was a positive correlation between 4% PEG-CICs and globulin (r = 0.43, P <0.0001).
In patients with LC, the level of Clq-CICs was higher than in controls (P<0.0001), while the 4% PEG-CIC level was lower than in controls (P<0.0001). There was no difference in the 3% PEG-CICs between LC patients and controls (Table I) .
AFP levels in patients with HCC, LC and controls The median level of AFP in patients with HCC (750; range 3-629 610 ng ml-') was significantly higher than that in patients with cirrhosis alone (median 3.7, range 3-110 ng ml') or controls (median 3.0; range 3.0-5.1 ng ml-') (each P<0.0001). The upper limit of normal AFP was defined as 20 ng ml-' (Chen and Sung, 1979; Sherlock and Dooley, 1993) . Serum AFP in all controls was lower than 20ngml-'. Sixteen (15.8%) patients with cirrhosis alone and 77 (76.2%) patients with HCC had an AFP level greater than 20 ng ml-'. In patients with cirrhosis alone, there was positive correlation between AFP and 3% PEGCICs (r = 0.23, P <0.002), AFP and 4% PEG-CICs (r = 0.22, P<0.030), AFP and Zy-glutamyltranspeptidase (r = 0.33, P<0.001). In patients with HCC, AFP was positively correlated with 4% PEG-CICs (r = 0.22, P<0.003). There was no correlation between AFP and 3% PEG-CICs or Clq-CICs (data not shown). Table IV . According to the ROC analysis, the optimal cut-off level for AFP was 120 .tg ml-', since up to this level the specificity improved without essentially decreasing the sensitivity, the resulting specificity being 100% and sensitivity 67.3%, with a diagnostic accuracy of 83.6%, a positive likelihood ratio greater than 67 and a negative likelihood ratio of 0.32 (Table  IV) . On the other hand, the recommended diagnostic level of HCC in Chinese was 400ngml-l (Chen and Sung, 1977) .
Using 400 ng ml-' as cut-off value, the sensitivity decreased to 63.7% but the specificity was still 100%. There was no significant difference between the diagnostic accuracies calculated from these two cut-off values (Table IV) .
In the ROC analysis, the optimal cut-off value for 3% PEG-CICs was 310 tg AIgG equiv.ml1', which gave a specificity of 100% at sensitivity level of 65.3%. The calculated diagnostic accuracy and positive and negative likelihood ratios were 82.6%, >65 aA, AFP (a-fetoprotein) > 400 ng ml; B, AFP > 120 ng ml-'; C, 3% PEG-CICs, (3% polyethylene glycol circulating immune complexes) 3 310 isg AIgG equiv. ml-'; bCalculated by using specificity >99%; cp<0.0001; dp<0.O00l. (Table IV) . Although the area under the ROC curve of AFP (0.875) was slightly higher than that of 3% PEG-CICs (0.812), there was no significant difference in the diagnostic efficiency when either marker was used. When both AFP and 3% PEG-CICs were determined in parallel, 17 (51.5%) of 33 HCC patients with AFP lower than 120 ng ml-' and 20 (54.0%) of 37 HCC patients with AFP lower than 400 ng ml' could be diagnosed. The resulting sensitivity is 83.1% and diagnostic accuracy 91.6% using AFP = 400 ng ml-' as cut-off point, or a sensitivity of 84.1% and diagnostic accuracy of 92.1% using AFP = 120 ng ml'. In either condition, the specificity is 100%, with a positive likelihood ratio greater than 83 and a negative likelihood ratio between 0.15 and 0.17 (Table IV) . As shown in Table  IV , the diagnostic accuracy of using both AFP and 3% PEG-CICs as markers was significantly higher than using AFP as marker alone (P <0.0001).
AFP and 3% PEG-CIC levels in relation to tumour size The echographic patterns of HCCs were classified into diffuse type (n = 27, 26.7%), nodular type (tumour size < 5 cm, n = 40, 39.6%) and massive type (tumour size > 5 cm, n = 34, 33.7%). There was no significant difference in the prevalence of raised AFP (> 120 ng ml-') or 3% PEG-CICs (>310 pg AIgG equiv. ml-') between patients with diffuse HCC and patients with non-diffuse HCC (66.6% vs 67.5% for AFP and 70.3% vs 63.5% for 3% PEG-CICs). When tumour size was divided into < 3 cm, > 3 -5 cm and > 5 cm in patients with non-diffuse HCC, the prevalence of raised AFP level was 41.6%, 71.4% and 73.5% respectively. The frequency of raised 3% PEG-CICs was 50% in tumours < 3 cm, 64.2% in tumours between 3 and 5 cm and 67.6% in tumours > 5 cm. The difference is not statistically significant. These results indicate that there is no relationship between tumour size (and/or echographic types of tumour) and levels of AFP and 3% PEG-CICs.
Discussion
The role of the liver in the clearance of immune complexes has been well established (Hopf et al., 1981) . Elevated CICs in patients with LC, as evidenced in this study (Table I) , might be due to decreased hepatic reticuloendothelial clearance, which has been shown to be impaired by experimental cirrhosis (Thomas et al., 1973) . The 3% PEG-CICs and 4% PEG-CICs levels were significantly higher in cirrhotic patients with HCC than in LC patients alone (Table I) . This implied that both CICs might relate to tumour mass. However, only 3% PEG-CICs were related, in a dose-response fashion, to tumour development after adjusting for impaired liver function with multivariate analysis (Table II) . In other words, 3% PEG-CICs may be correlated with tumour burden . Our results of higher 3% PEG-CIC and lower 4% PEG-CIC levels in HCC patients suggests that the CICs elevated in HCC are larger than in healthy controls (Zubler et al., 1977) (Table I ).
Based on the significant difference in CICs between cirrhotic HCC patients and LC patients, an attempt was made to differentiate HCC from patients with LC by CICs. For clinical decision making, the selected cut-off value of a laboratory test should provide the best diagnostic performance for either ruling out or ruling in the particular disease.
The ROG curve analysis is a graphic method which can be used to determine this optimal cut-off level. In addition, it is a precise and valid measure of diagnostic accuracy (Swets, 1988) . In this study, the calculated area under the ROC curve of AFP (0.875) and 3% PEG-CICs (0.812) is between 0.7 and 0.9, which indicates that both markers are useful for diagnostic purpose (Swets, 1988) .
During recent years various serological markers have been developed in the diagnosis of HCC (Maussier et al., 1990; Fujiyama et al., 1992; Kasahara et al., 1993; Sherlock and Dooley, 1993; Chuang et al., 1994) . Serum AFP is among the most intensively studied tumour markers. Using ROC analysis, the normal AFP was 5.2 ng ml- (Maussier et al., 1990) . In cirrhotic patients with AFP values higher than 18.5 ng ml' the likelihood of HCC being present is 95% (Maussier et al., 1990) . A cut-off value of 150ngml1' for diagnosis of HCC was suggested previously (Fujiyama et al., 1992) . The diagnostic level of AFP in China is 400ngmlh' (Chen and Sung, 1977) . As shown in this study, AFP levels less than 400 ng ml' were found in 36.6% (37/101) of HCC patients at the time of tumour detection. It is obvious that AFP alone is not a reliable indicator for detection of HCC in patients with a low AFP level. Therefore, additional and more sensitive diagnostic tools must be sought. In this study, regardless of which cut-off value (120 ng ml' or 400ngml-') was selected, AFP showed a good specificity (100%) and moderate sensitivity (67.3% or 63.3% respectively) and a high positive likelihood ratio (Table IV) . Based on the selected optimal cut-off value by ROC curve analysis, 3% PEG-CICs showed a high specificity (100%) and moderate sensitivity (65.3%). However, determination of AFP and 3% PEG-CICs in parallel significantly increased the diagnostic accuracy (Table IV) . Although each test may not have sufficient sensitivity, the simultaneous use of both tests may be highly discriminatory in the detection of HCC. However, the combined positive predictive value will not be different from parallel assays if each positive assay is deemed clinically positive (Table IV) . Parallel detection of both markers increases the number of tests performed, and this must have cost implications. As the cost of determining 3% PEG-CICs is low, and the test is easy to perform, the assay for 3% PEG-CICs should be performed to improve the detection of HCC in AFP-negative cirrhotics.
Elevation of AFP may be seen in patients with 'active' liver disease (Chen and Sung, 1977; Sherlock and Dooley, 1993) . CICs may also be increased in patients with chronic liver disease (Brown et al., 1983 (Brown et al., , 1984 Coursaget et al., 1986; Tsai et al., 1990a Tsai et al., ,b, 1991 Tsai et al., , 1995a . Such elevations may have an important effect upon the specificity of the tests. In this study, none of the patients with cirrhosis alone had AFP or 3% PEG-CICs greater than the optimal cut-off points selected by ROC curve analysis.
The major aim of tumour marker estimation in HCC is as a means of early detection (surveillance), particularly in the cirrhotic population. The present analysis has looked at a population of patients with a histologically proven diagnosis of HCC. It may be assumed that many of these had advanced disease and thus a high proportion would have significantly elevated tumour marker levels. The high specificity and sensitivity attained might therefore be overestimating the value of these tests as a surveillance tool. This clearly requires further evaluation.
In conclusion, this study shows that addition of an assay for 3% PEG-CICs to AFP gives a significant improvement in detection of HCC in patients with cirrhosis. The optimal cut-off value for AFP in the diagnosis of cirrhotic HCC is 120ILgml-'. In addition, 3% PEG-CICs should be used as an adjunctive tool in the detection of HCC in cirrhotics negative for AFP.
